Abstract:Significance: Protein neddylation is catalyzed by an E1 NEDD8-activating enzyme (NAE), an E2 NEDD8-conjugating enzyme, and an E3 NEDD8 ligase. Known physiological substrates of neddylation are cullin family members. Cullin neddylation leads to activation of cullin-RING ligases (CRLs), the largest family of E3 ubiquitin ligases responsible for ubiquitylation and degradation of many key signaling/regulatory proteins. Thus, through modulating CRLs, neddylation regulates many biological processes, including cell cycle progression, signal transduction, and tumorigenesis. Given that NEDD8 is overexpressed and CRLs are abnormally activated in many human cancers, targeting protein neddylation, in general, and cullin neddylation, in particular, appears to be an attractive anticancer approach. Recent Advances: MLN4924, a small molecule inhibitor of NAE, was discovered that inactivates CRLs and causes accumulation of CRL substrates to suppress tumor cell growth both in vitro and in vivo. Promising preclinical results advanced MLN4924 to several clinical trials for anticancer therapy. Critical Issues: In preclinical settings, MLN4924 effectively suppresses tumor cell growth by inducing apoptosis, senescence, and autophagy, and causes sensitization to chemoradiation therapies in a cellular context-dependent manner. Signal molecules that determine the cell fate upon MLN4924 treatment, however, remain elusive. Cancer cells develop MLN4924 resistance by selecting target mutations. Future Directions: In the clinical side, several Phase 1b trials are under way to determine the safety and efficacy of MLN4924, acting alone or in combination with conventional chemotherapy, against human solid tumors. In the preclinical side, the efforts are being made to develop additional neddylation inhibitors by targeting NEDD8 E2s and E3s. Antioxid. Redox Signal. 21, 2383-2400.

Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo

Discovery of Candesartan Cilexetic As a Novel Neddylation Inhibitor for Suppressing Tumor Growth

Identification of novel benzoyl hydrazine derivatives as activators of neddylation pathway to inhibit the tumor progression in vitro

Identification of novel benzothiazole derivatives as inhibitors of NEDDylation pathway to inhibit the progression of gastric cancer

Discovery of the 2,4-Disubstituted Quinazoline Derivative As a Novel Neddylation Inhibitor for Tumor Therapy

Discovery of Benzothiazole Derivatives As Novel Non-Sulfamide NEDD8 Activating Enzyme Inhibitors by Target-Based Virtual Screening.

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression <i>in vitro</i> and <i>in vivo</i>

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

Targeting cullin neddylation for cancer and fibrotic diseases

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Structure-based Design and Synthesis of Imidazo[1,2-A]pyridine Derivatives As Novel and Potent Nek2 Inhibitors with in Vitro and in Vivo Antitumor Activities

Protein Neddylation and Its Alterations in Human Cancers for Targeted Therapy.

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Progress in the researches for antitumor NEDD8 activating enzyme inhibitors

Anticancer Drug Discovery by Targeting Cullin Neddylation

SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy

Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy

A Small Molecule Inhibitor of the UBE2F-CRL5 Axis Induces Apoptosis and Radiosensitization in Lung Cancer

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway